- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00420121
European Society of Cutaneous Lupus Erythematosus (EUSCLE)
European Society of Cutaneous Lupus Erythematosus
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
NRW
-
Muenster, NRW, Germany, 48149
- University of Muenster, Department of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- systemic or cutaneous lupus erythematosus confirmed by histological analysis
- written informed consent available prior to any study-procedures
Exclusion Criteria:
- patients with conditions that are contrary to the above mentioned criteria
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Activity and Damage of Skin Lesions in Patients with Cutaneous Lupus Erythematosus measured by the RCLASI Activity and Damage Score.
Time Frame: Up to 12 months
|
The Total RCLASI Activity Score measures (i) the activity of skin lesions by evaluating the parameters "erythema", "scaling ⁄hyperkeratosis", "oedema ⁄Infiltration", and "subcutaneous nodule ⁄plaque" and/or (ii) the activity of mucous membrane lesions and/or (iii) the activity of alopecia. The Total RCLASI Damage Score measures (i) the damage of skin lesions by evaluating the parameters "dyspigmentation" and "scarring/atrophy" and/or (ii) the damage of scarring alopecia. |
Up to 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Annegret Kuhn, MD, University of Muenster, Department of Dermatology
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2742-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lupus Erythematosus, Systemic
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...CompletedSystemic Lupus Erythematosus | Cutaneous Lupus ErythematosusSpain, Bulgaria, Germany, Moldova, Republic of, North Macedonia, Ukraine
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
Clinical Trials on laboratory analysis
-
University Hospital OstravaCompletedRhabdomyolysis | Tissue Injury | Major TraumaCzechia
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
HaEmek Medical Center, IsraelCompleted
-
HaEmek Medical Center, IsraelUniversity of Zurich; University of PalermoTerminated
-
European Society of Cutaneous Lupus Erythematosus...Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCTerminatedLymphoma | Nonneoplastic ConditionUnited States
-
China National Center for Cardiovascular DiseasesPeking Union Medical College HospitalRecruiting
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedPancreatic CancerUnited States